SERPINF2 and metabolic syndrome: Meanwhile, Api receivers showed markedly mitigated HFD-induced blood glucose increase accompanied by improvement in insulin resistance (Figures 5G,H), ameliorated dyslipidemia (Figure 5I), restoration of liver injury (Figure 5J), and improved inflammatory cytokines in serum (Figure 5K).